Drug Trial Radar · NCT06226545
A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease
Last checked: Nov 19, 2026Latest source record: Mar 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
41
Actual
Start
Mar 5, 2024
Primary completion
Apr 22, 2025
Study completion Apr 22, 2025
Sponsor
- Lead sponsor
- Lassen Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
LASN01 is a novel, fully human antibody directed against the human IL-11 receptor being developed for treatment of patients with thyroid eye disease (TED). The primary and secondary objectives of this study are to evaluate the treatment effect, safety, and pharmacokinetics of LASN01 administered IV in patients with TED with no prior anti-IGF-1R treatment or in patients with TED who have previously received teprotumumab treatment.
Conditions
- Thyroid Eye Disease
- Graves Ophthalmopathy
- Graves Orbitopathy
- Thyroid Associated Ophthalmopathy
- Endocrine System Diseases
- Orbital Diseases
- Proptosis
- Eye Diseases
Interventions
LASN01Drug
Low dose of LASN01 will be administered intravenously.
LASN01Drug
High dose of LASN01 will be administered intravenously.
PlaceboDrug
Placebo will be administered intravenously.
LASN01Drug
High dose of LASN01 will be administered intravenously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Showing a Response in Proptosis Measured Using Hertel Exophthalmometer (≥2 mm Decrease From Baseline) in the Study Eye and Separately in Either Eye Without Increased Proptosis (≥2 mm Increase) in the Other EyeTime frame: Day 1-Day 253
- For Randomized Treatment Arms: Number of Participants With Adverse Events Receiving LASN01 Compared to PlaceboTime frame: Day 1-Day 393
- For Open-label Treatment Arm: Number of Participants With Adverse Events Receiving LASN01Time frame: Day 1-Day 393
Locations
15 sites in 3 countries. Site status is shown where the registry gives one.
Site 111
Beverly Hills, California
Site 105
Palo Alto, California
Site 101
San Diego, California
Site 103
Miami, Florida
Site 108
Livonia, Michigan
Site 112
Las Vegas, Nevada
Site 110
Wilmington, North Carolina
Site 106
Houston, Texas
Site 104
Houston, Texas
Site 109
Seattle, Washington
Site 302
Córdoba, Spain
Site 301
Seville, Spain
Site 201
London, United Kingdom
Site 206
London, United Kingdom
Site 204
Newcastle upon Tyne, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.